卡莫司汀缓释片(Gliadel®)植入治疗高级别胶质瘤:一项为期9年的全国回顾性研究
该研究基于法国国家医疗行政数据库,回顾2010至2018年间39家机构共1659例接受卡莫司汀缓释片植入的高级别胶质瘤患者,分析其流行病学、并发症、长期生存及预后因素。中位总生存期为1.4年(95%CI 1.3-1.5),1年与2年总生存率分别为66%(95%CI 63.7-68.5)与32.3%(95%CI 29.9-35)。男性与植入时年龄为独立预后因素,复发患者预后显著更差(HR=0.71,95%CI 0.62-0.80,P<0.001),术后感染或颅内出血导致再手术与总生存下降无关联。
要点
- 9年间法国卡莫司汀缓释片使用显著减少,共1659例患者于39家机构接受植入。
- 中位总生存期1.4年,1年与2年总生存率分别为66%与32.3%。
- 复发高级别胶质瘤患者预后显著更差(HR=0.71,95%CI 0.62-0.80,P<0.001)。
核心结论
- 过去9年法国卡莫司汀缓释片的使用显著减少。
- 植入后总生存受年龄、性别或复发疾病等因素影响而显著不同,但不受术后并发症影响。
- 与既往结果相比,卡莫司汀缓释片可能提高总生存,且该效应在给予辅助放疗/替莫唑胺时似乎更明显。
研究设计与样本
- 法国全国医疗行政数据库回顾性研究,检索2010年至2018年间接受手术的合适病例。
- 共识别39家机构治疗的1659例患者,并进行了生存分析。
主要发现
- 植入时中位年龄61岁,男性占63.5%。
- 491例(29.6%)既往已诊断胶质瘤,首次手术与卡莫司汀缓释片植入间隔0.9年,IQR[0.6, 1.6]。
- 额叶最常受累,占29%。
- 131例(7.9%)因并发症需再手术,其中121例为手术部位感染。
- 1年时514例(31%)死亡;中位总生存期1.4年,95%CI [1.3, 1.5];1年与2年总生存率分别为66%(95%CI [63.7, 68.5])与32.3%(95%CI [29.9, 35])。
关键数值与推荐
- 调整后Cox回归中,男性与植入时年龄在三组中均被确立为总生存的独立因素。
- 复发高级别胶质瘤患者预后显著更差(HR=0.71,95%CI [0.62, 0.80],P<0.001)。
- 术后诊断感染或颅内出血最终导致再手术与总生存下降无关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Carmustine wafers (CW) are approved to treat newly or recurrent high-grade gliomas (HGG). Widespread use has been limited regarding some doubtful uncertainties about their efficacy, related increased risk of infection and expensive cost. OBJECTIVE: To describe the epidemiology of CW implantation, search for related complications, long-term survival and associated prognostic factors. METHODS: We processed the French medico-administrative national database to retrieve appropriate cases operated between 2010 and 2018. A survival analysis was conducted. RESULTS: We identified 1659 patients treated in 39 institutions. Median age at CW implantation was 61 years and there was an over-representation of male (63.5%). 491 patients (29.6%) had previous diagnosis of glioma. Time between the first surgery and CW implantation was 0.9 years, IQR[0.6, 1.6]. The frontal lobe was the most frequently involved 29%. 131 patients (7.9%) had to be re operated on for a complication of which 121 for surgical site infection. At one year, 514 patients (31%) had died. Median overall survival (OS) was 1.4 years, 95% CI [1.3, 1.5]. OS at 1 and 2 year was 66%, 95%CI [63.7, 68.5], 32.3%, 95%CI [29.9, 35]. In the adjusted Cox regression, male gender & age at CW implantation were established as independent factors of OS in all three groups. Patients with recurrent HGG have a significant worse prognosis (HR = 0.71, 95% CI [0.62, 0.80] p < 0.001). A post-operative diagnosis of infection or intracranial bleeding eventually leading to a redo surgery was not associated with a decrease OS. CONCLUSION: Over the past 9 years, there is a significant decrease utilisation of CW in France. OS after CW implantation is significantly variable as influenced by many factors such as age, gender or recurrent disease but not by post-operative complications. Compare to previous results, CW may increase the OS and this effect seems more pronounced when adjuvant RT/TMZ is given.
引用
- Champeaux C, Weller J. Implantation of carmustine wafers (Gliadel®) for high-grade glioma treatment. A 9-year nationwide retrospective study. J Neurooncol. 2020. PMID: 31974802. doi:10.1007/s11060-020-03410-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。